Asia Pacific Cancer Immunotherapy Market Size & Outlook

The cancer immunotherapy market in Asia Pacific is expected to reach a projected revenue of US$ 71,890.9 million by 2033. A compound annual growth rate of 10.6% is expected of Asia Pacific cancer immunotherapy market from 2026 to 2033.
Revenue, 2025 (US$M)
$32,316.0
Forecast, 2033 (US$M)
$71,890.9
CAGR, 2026 - 2033
10.6%
Report Coverage
Asia Pacific

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Asia Pacific cancer immunotherapy market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Asia Pacific cancer immunotherapy market highlights

  • The Asia Pacific cancer immunotherapy market generated a revenue of USD 32,316.0 million in 2025.
  • The market is expected to grow at a CAGR of 10.6% from 2026 to 2033.
  • In terms of segment, monoclonal antibodies was the largest revenue generating product in 2025.
  • Oncolytic Viral Therapies and Cancer Vaccines is the most lucrative product segment registering the fastest growth during the forecast period.
  • Country-wise, India is expected to register the highest CAGR from 2026 to 2033.


Asia Pacific data book summary

Market revenue in 2025USD 32,316.0 million
Market revenue in 2033USD 71,890.9 million
Growth rate10.6% (CAGR from 2026 to 2033)
Largest segmentMonoclonal antibodies
Fastest growing segmentOncolytic Viral Therapies and Cancer Vaccines
Historical data covered2021 - 2024
Base year for estimation2025
Forecast period covered2026 - 2033
Quantitative unitsRevenue in USD million
Market segmentationMonoclonal Antibodies, Check Point Inhibitors, Oncolytic Viral Therapies and Cancer Vaccines
Key market players worldwidePfizer Inc, AstraZeneca PLC, Merck & Co Inc, Roche Holding AG, Bristol-Myers Squibb Co, Novartis AG ADR, Eli Lilly and Co, Johnson & Johnson, Immunocore Holdings PLC ADR


Other key industry trends

  • In terms of revenue, Asia Pacific region accounted for 21.1% of the global cancer immunotherapy market in 2025.
  • Globally, North America is projected to lead the regional market in terms of revenue in 2033.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 71,890.9 million by 2033.

Monoclonal antibodies was the largest segment with a revenue share of 69.57% in 2025. Horizon Databook has segmented the Asia Pacific cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2021 to 2033.


The cancer immunotherapy market in Asia Pacific is expected to grow at a significant rate during the forecast period due to the presence of leading oncology companies and increase in R&D investments in countries such as China and Japan.

This, in turn, has led to an increase in the development of cancer drugs. Moreover, the cost of clinical trials in developing countries is lesser than that in developed countries. In addition, developing countries such as India and China are witnessing an increase in population and disposable income.

High incidence of cancer in this region has resulted in an increase in the demand for improved therapeutics, rise in government funding for cancer & other research, and increase in healthcare expenditure. Thus, these factors are expected to drive market growth in Asia Pacific during the forecast period.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cancer Immunotherapy Market Companies

Name Profile # Employees HQ Website
Immunocore Holdings PLC ADR View profile 497 92 Park Drive, Milton Park, Abingdon, Oxfordshire, United Kingdom, OX14 4RY https://www.immunocore.com
AstraZeneca PLC View profile 89900 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA https://www.astrazeneca.com
Eli Lilly and Co View profile 43000 Lilly Corporate Center, Indianapolis, IN, United States, 46285 https://www.lilly.com
Bristol-Myers Squibb Co View profile 34100 Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 https://www.bms.com
Merck & Co Inc View profile 72000 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 https://www.merck.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
Novartis AG ADR View profile 76057 Lichtstrasse 35, Basel, Switzerland, 4056 https://www.novartis.com
Johnson & Johnson View profile 134400 One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 https://www.jnj.com

Asia Pacific cancer immunotherapy market size, by country, 2021-2033 (US$M)

Asia Pacific Cancer Immunotherapy Market Outlook Share, 2025 & 2033 (US$M)

Asia Pacific cancer immunotherapy market size, by country, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online